drugset / Trial / NCT01070615

Study to Evaluate Long-Term Tolerability and Safety of Oral Prucalopride in Chronic Constipation

NCT01070615

Phase 3 Completed 693 enrolled Movetis
NaSingle-groupOpen-labelTreatment

Summary

Objectives: Evaluation of the clinical long-term safety, tolerability, patient satisfaction, pharmacokinetics and pattern of use of oral prucalopride tablets given in doses up to 4 mg once daily to patients with chronic constipation

Timeline

Start
1998-06
Primary completion
2000-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Prucalopride Small molecule 4 mg Oral

Indications